Exicure, formerly AuraSense Therapeutics, is developing a new class of immunomodulatory and gene-silencing drugs against validated targets. Their 3-D, spherical nucleic acid architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Their lead programs address diseases from inflammatory disorders to oncology.